Health Care & Life Sciences » Biotechnology | Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
222.86 M
Public Float
213.41 M
Alexion Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.82
Market Cap
$29.22 B
Shares Outstanding
224.24 M
Public Float
222.46 M

Profile

Address
121 Seaport Boulevard
Boston Massachusetts 02210
United States
Employees -
Website http://www.alexion.com
Updated 07/08/2019
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A.

Financials

View All
Created with Highcharts 5.0.14Alexion Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Millions.25325365765714414439939944344378782013201420152016201720180200400600800
Created with Highcharts 5.0.14Alexion Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Millions.1 5121 5122 2152 2152 4862 4863 0113 0113 5323 5324 1334 13320132014201520162017201801k2k3k4k5k

Ludwig N. Hantson
Chief Executive Officer & Director
David Richard Brennan
Chairman